NEW YORK (GenomeWeb News) – Rosetta Genomics announced after the close of the market on Tuesday that it has revised its co-marketing deal with Precision Therapeutics.

Under the revised terms, reached on Oct. 11, Rosetta grants Precision co-exclusive rights to market the miRview mets2 assay in the US. Once a minimum number of tests ordered through Precision is reached in a given month, Rosetta will pay Precision a flat monthly fee, a Rosetta spokesperson said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.